WO2002056708A3 - Zubereitung zur verbesserung der nahrungsverwertung - Google Patents

Zubereitung zur verbesserung der nahrungsverwertung Download PDF

Info

Publication number
WO2002056708A3
WO2002056708A3 PCT/EP2002/000370 EP0200370W WO02056708A3 WO 2002056708 A3 WO2002056708 A3 WO 2002056708A3 EP 0200370 W EP0200370 W EP 0200370W WO 02056708 A3 WO02056708 A3 WO 02056708A3
Authority
WO
WIPO (PCT)
Prior art keywords
utilisation
dietary
preparation
preparations
improved dietary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/000370
Other languages
English (en)
French (fr)
Other versions
WO2002056708A2 (de
Inventor
Klaus Kraemer
Oliver Hasselwander
Uwe Oberfrank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Priority to US10/250,567 priority Critical patent/US7304089B2/en
Priority to CA002435077A priority patent/CA2435077A1/en
Priority to JP2002557224A priority patent/JP2004520036A/ja
Priority to EP02715439A priority patent/EP1353569A2/de
Publication of WO2002056708A2 publication Critical patent/WO2002056708A2/de
Publication of WO2002056708A3 publication Critical patent/WO2002056708A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)

Abstract

Die vorliegende Erfindung betrifft Lebensmittel-, Nahrungsmittel- oder Arzneimittelzubereitungen, die konjugierte trans/cis Octadecatriensäure enthalten sowie Verfahren zu iher Herstellung. Erfindungsgemäβe Zubereitungen enthalten vorzugsweise Calendulasäure. Die Erfindung betrifft zudem die Verwendung der Zubereitungen zur Redutkion der Nahrungsaufnahme bei Menschen und Tieren und zur besseren Nahrungsverwertung.
PCT/EP2002/000370 2001-01-17 2002-01-16 Zubereitung zur verbesserung der nahrungsverwertung Ceased WO2002056708A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/250,567 US7304089B2 (en) 2001-01-17 2002-01-16 Preparation for improved dietary utilisation
CA002435077A CA2435077A1 (en) 2001-01-17 2002-01-16 Preparation for improved dietary utilisation
JP2002557224A JP2004520036A (ja) 2001-01-17 2002-01-16 食物利用率を改良するための調製物
EP02715439A EP1353569A2 (de) 2001-01-17 2002-01-16 Zubereitung zur verbesserung der nahrungsverwertung

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10102050.3 2001-01-17
DE10102050A DE10102050A1 (de) 2001-01-17 2001-01-17 Zubereitung zur Verbesserung der Nahrungsverwertung

Publications (2)

Publication Number Publication Date
WO2002056708A2 WO2002056708A2 (de) 2002-07-25
WO2002056708A3 true WO2002056708A3 (de) 2002-11-07

Family

ID=7670919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000370 Ceased WO2002056708A2 (de) 2001-01-17 2002-01-16 Zubereitung zur verbesserung der nahrungsverwertung

Country Status (7)

Country Link
US (1) US7304089B2 (de)
EP (1) EP1353569A2 (de)
JP (2) JP2004520036A (de)
AR (1) AR032248A1 (de)
CA (1) CA2435077A1 (de)
DE (1) DE10102050A1 (de)
WO (1) WO2002056708A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10158046A1 (de) * 2001-11-27 2003-06-05 Basf Ag Formulierung für den Einsatz in Lebensmitteln, Nahrungsergänzungsmitteln, Futtermitteln, Futterzusatzstoffen, pharmazeutischen und kosmetischen Zubereitungen sowie Verfahren zu deren Herstellung
WO2005063230A1 (en) * 2003-12-30 2005-07-14 Universite Laval Use of conjugated linolenic acids for reducing body fat mass
JP2005264077A (ja) * 2004-03-19 2005-09-29 Nisshin Oillio Group Ltd 共役型トリエン酸含有油脂組成物及びその油脂の製造方法
JP4772295B2 (ja) * 2004-06-22 2011-09-14 学校法人順天堂 共役脂肪酸を有効成分とする運動能力改善剤
AU2005281393B2 (en) * 2004-09-09 2012-01-12 Virbac (Australia) Pty Ltd Trace elements
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
CA2605855A1 (en) * 2005-04-29 2006-11-09 Hill's Pet Nutrition, Inc. Methods for prolonging feline life
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound
GB0814105D0 (en) * 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
WO2011057731A1 (en) * 2009-11-10 2011-05-19 Cognis Ip Management Gmbh A composition comprising a lipid suitable for human consumption
MX348659B (es) * 2010-11-19 2017-05-08 Centro De Innovacion Biotecnologica A C Alimentos funcionales con altos contenidos de harina de soya (sbm), almidon y bacillus ssp.
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
EP3131409B1 (de) * 2014-03-13 2025-06-25 Basf Se Pelletiertes wiederkäuerfutter angereichert mit pansen-labilen inhaltsstoffen
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CA2951923A1 (en) 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
ES2827796T3 (es) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Composiciones y procedimientos relativos a sales de mediadores pro-resolutivos especializados de inflamación
CN115462456B (zh) * 2022-08-19 2024-03-15 金金 一种冬季用肉羊中草药饲料添加剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011176A2 (en) * 1998-08-20 2000-03-02 E.I. Du Pont De Nemours And Company Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation
WO2000062772A1 (en) * 1999-04-15 2000-10-26 Kaneka Corporation Peroxisome activator-responsive receptor agonists
JP2000336029A (ja) * 1999-05-28 2000-12-05 Rinoru Oil Mills Co Ltd 共役リノレン酸を有効成分とする乳癌抑制剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1156788C2 (de) 1959-12-02 1973-11-22 Brinckmann Harburger Fett Verfahren zur Umwandlung von Fettsaeureestern einwertiger Alkohole mit isolierten Doppelbindungen (íÀIsolenfettsaeureesterníÂ) in Fettsaeureester mit konjugierten Doppelbindungen (íÀKonjuenfettsaeureesteríÂ)
DE1156789B (de) 1960-04-16 1963-11-07 Brinckmann Harburger Fett Verfahren zur Umwandlung von Fettsaeureestern einwertiger Alkohole mit isolierten Doppelbindungen (íÀIsolenfettsaeureesterníÂ) in Fettsaeureester mit konjugierten Doppelbindungen (íÀKonjuenfettsaeureesteríÂ)
SE303998B (de) 1959-12-02 1968-09-16 Brinckmann Harburger Fett
GB921688A (en) 1960-09-15 1963-03-20 Nippon Storage Battery Mfg Com Improvements in and relating to plates for lead-acid batteries
US3356694A (en) 1964-08-20 1967-12-05 Syntex Corp 3-keto-4-methylene derivatives of the androstane and pregnane series and process therefor
US3356699A (en) 1965-06-09 1967-12-05 Marvin O Bagby Alkali isomerization of crepenynic acid to 8, 10, 12-octadecatrienoic acid
US5554646A (en) 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5428072A (en) 1992-04-29 1995-06-27 Wisconsin Alumni Research Foundation Method of increasing the efficiency of feed conversion in animals
US5376374A (en) * 1993-05-24 1994-12-27 Zelaya; Luz M. Oral rinse composition
US5814663A (en) 1994-08-29 1998-09-29 Wisconsin Alumni Research Foundation Method for maintaining an existing level of body fat
US5760082C1 (en) 1994-08-29 2001-03-06 Wisconsin Alumni Res Found Dietetic foods containing conjugated linoleic acids
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5585400A (en) 1996-02-27 1996-12-17 Wisconsin Alumni Research Foundation Methods of attenuating the allergic response in animals
DE19638729B4 (de) * 1996-09-13 2004-09-23 Lancaster Group Gmbh Stabile Mehrphasenemulsion vom Typ 01/W/O2, Verfahren zu ihrer Herstellung sowie ihre Verwendung
JP3017108B2 (ja) 1996-10-30 2000-03-06 リノール油脂株式会社 共役リノール酸の製造方法
CA2313626A1 (en) 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes
US6197305B1 (en) * 1998-01-05 2001-03-06 Farmo-Nat Ltd. Anti-fungal compositions with prolonged activity
CA2339871A1 (en) 1998-08-20 2000-03-02 Abbott Laboratories Nucleic acids encoding a functional human purinoreceptor p2x2 and methods of producing and use thereof
US6444238B1 (en) * 2000-03-10 2002-09-03 General Cosmetics Corporation Pain relief composition and method of relieving pain
US20020045232A1 (en) * 2000-05-09 2002-04-18 Xiao Qiu Production of conjugated linoleic and linolenic acids in plants

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011176A2 (en) * 1998-08-20 2000-03-02 E.I. Du Pont De Nemours And Company Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation
WO2000062772A1 (en) * 1999-04-15 2000-10-26 Kaneka Corporation Peroxisome activator-responsive receptor agonists
EP1175901A1 (de) * 1999-04-15 2002-01-30 Kaneka Corporation Agonisten des peroxisom aktivator-responsiven rezeptors
JP2000336029A (ja) * 1999-05-28 2000-12-05 Rinoru Oil Mills Co Ltd 共役リノレン酸を有効成分とする乳癌抑制剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANNALS OF NUTRITION AND METABOLISM, vol. 42, no. 5, October 1998 (1998-10-01), pages 290 - 296 *
DHAR P ET AL: "DIETARY EFFECTS OF CONJUGATED OCTADECATRIENOIC FATTY ACID (9 CIS, 11 TRANS, 13 TRANS) LEVELS ON BLOOD LIPIDS AND NONENZYMATIC IN VITRO LIPID PEROXIDATION IN RATS", LIPIDS, CHAMPAIGN, IL, US, vol. 34, no. 2, February 1999 (1999-02-01), pages 109 - 114, XP000973904, ISSN: 0024-4201 *
DHAR P ET AL: "Nutritional characteristics of oil containing conjugated octadecatrienoic fatty acid", BIOSIS, PREV 199900002659, XP002162410 *
NUGTEREN D H ET AL: "NATURALLY OCCURRING CONJUGATED OCTADECATRIENOIC ACIDS ARE STRONG INHIBITORS OF PROSTAGLANDIN BIOSYNTHESIS", PROSTAGLANDINS, BUTTERWORTH, STONEHAM, MA, US, vol. 33, no. 3, 1 March 1987 (1987-03-01), pages 403 - 417, XP002063858, ISSN: 0090-6980 *
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 15 6 April 2001 (2001-04-06) *
TAKAGI T ET AL: "OCCURRENCE OF MIXTURES OF GEOMETRICAL ISOMERS OF CONJUGATED OCTADECATRIENOIC ACIDS IN SOME SEED OILS: ANALYSIS BY OPEN-TUBULAR GAS LIQUID CHROMATOGRAPHY AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY", LIPIDS, CHAMPAIGN, IL, US, vol. 16, no. 7, July 1981 (1981-07-01), pages 546 - 551, XP000973303, ISSN: 0024-4201 *
YURAWECZ ET AL.: "Estimation of Conjugated Octadecatrienes in Edible Fats and Oils", JOURNAL OF THE AMERICAN OIL CHEMISTS' SOCIETY., vol. 70, no. 11, November 1993 (1993-11-01), AMERICAN OIL CHEMISTS' SOCIETY. CHAMPAIGN., US, pages 1093 - 1099, XP002207591, ISSN: 0003-021X *

Also Published As

Publication number Publication date
JP2009132721A (ja) 2009-06-18
DE10102050A1 (de) 2002-07-18
JP2004520036A (ja) 2004-07-08
WO2002056708A2 (de) 2002-07-25
CA2435077A1 (en) 2002-07-25
AR032248A1 (es) 2003-10-29
US7304089B2 (en) 2007-12-04
EP1353569A2 (de) 2003-10-22
US20040047894A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2002056708A3 (de) Zubereitung zur verbesserung der nahrungsverwertung
AU2002342968A1 (en) Fatty acid compounds, preparation and uses thereof
WO2001058271A8 (en) Nutritional supplements for aged pets
EP1911453A3 (de) Immunmodulierende Oligosaccharide
WO2004043906A3 (de) Verwendung von trans-pellitorin als aromastoff
HK1048579A1 (zh) 改善中年以上的宠物的条件
AU2002243005A1 (en) Vital cell preparations containing lactic acid bacterium as the active ingredient and lactic acid bacterium-containing foods
IL161995A (en) Purified strain of lactic acid bacterium and uses thereof in the preparation of edible compositions, drugs and veterinary products
MXPA03007758A (es) Composicion alimenticia compuesta que comprende un gel y proceso para su preparacion.
EP1300084A3 (de) Zusammensetzung zur Behandlung von chronischer venöser Insuffizienz mit einem Extrakt aus Blättern von roten Weinreben
AU2001236616A1 (en) Improved stability conjugated linoleic acid composition for dietary supplement and food uses
WO2002005830A3 (en) Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
WO2004039326A3 (en) Propofol with cysteine
AU2003221135A1 (en) New strains capable of producing conjugated linoleic acid, capsulated composition comprising them, and the preparation methods thereof
WO2006109194A3 (en) Chromium-fatty acid compounds and methods of making and using thereof
WO2002098442A3 (de) Phytasehaltige zusammensetzung
WO2002087604A3 (de) Präparationen von vitamin e in kombination mit afamin
TW200626073A (en) Activated globular protein and its use in edible compositions
EP1167532A3 (de) Essbare transgene Pflanzen, die Säugerproteine exprimieren
WO2001089315A3 (en) Method of enhancing growth, fluid consumption and feed conversion in birds
FR2829692B1 (fr) Composition selective de six categories de substances preservant l'equilibre physiologique chez l'homme comprenant un complexe de micronutriments,un complexe d'antioxydants et un complexe d'acides gras.
IL174691A0 (en) Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient
WO2005087017A3 (en) Compositions comprising reverse isomers of conjugated linoleic acid
WO2003037375A1 (fr) Substance d'induction de cytokine et instrument d'induction de cytokine
AU2002219949A1 (en) Dietary composition containing conjugated linoleic acid and calcium for improved health

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002715439

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10250567

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2002557224

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2435077

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002715439

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642